Posttraumatic stress disorder symptoms in systemic autoimmune rheumatic disease patients during the early COVID‐19 pandemic

Abstract

AbstractAimGiven reports of increased prevalence of PTSD symptoms at COVID‐19 pandemic onset, we aimed to assess the prevalence of posttraumatic stress disorder (PTSD) symptoms at pandemic onset in individuals with and without systemic autoimmune rheumatic disease (SARD).MethodsIn May 2020, we invited 6678 patients to complete the Brief Trauma Questionnaire and the Posttraumatic Stress Disorder Checklist (PCL‐5), validated PTSD symptom screenings. We compared responses from patients with and without SARD using multivariable logistic regression.ResultsWe received 1473 responses (22% response rate) from 5/2020 to 9/2021 (63 with prior PTSD diagnoses, 138 with SARD history). The SARD population was more female (p .0001) and had a higher baseline prevalence of stress disorders (56% vs. 43%, p .004). SARD subjects reported more experiences with life‐threatening illness, 60%, versus 53% among those without SARD (p .13), and more antidepressant or anxiolytic medication use pre‐pandemic (78% vs. 59%, p .0001). Adjusting for pre‐pandemic PTSD diagnosis, younger age and history of stress disorder were the most significant predictors of PCL‐5 positivity. There were no significant differences in PCL‐5 score or positivity among those with or without SARD.ConclusionIn this population, patients with SARD had a higher pre‐COVID‐19 prevalence of stress‐related conditions, but it was not the case that they had an increased risk of PTSD symptoms in the early pandemic. Younger individuals, those with baseline depression, anxiety, or adjustment disorders, and those taking antidepressant or anxiolytic medications were more likely to have PTSD symptoms in the first waves of the COVID‐19 pandemic.